bucillamine
Small moleculeexperimental
Bucillamine is an antirheumatic agent developed from tiopronin. Activity is mediated by the two thiol groups that the molecule contains. Research done in USA showed positive transplant preservation properties. Bucillamine is currently being investigated for COVID-19 drug repurposing. — Wikipedia
Clinical trial activity
6 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
5
Phase 3
3
Phase 4
1
Earliest trial started Jan 1, 2007 (NCT00716248)
Timeline
Indications
Approved for
Mechanism of action
- Unspecified targetOTHER
Antioxidant
May also have anti-inflammatory effects.
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)(S)C(=O)N[C@H](CS)C(=O)O- Mol. weight
- 223.32 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaBucillamine ↗
- ChEMBLCHEMBL80830 ↗
- ChEMBLCHEMBL2104131 ↗
Also known as
- 2-mercapto-2-methylpropanoyl-l-cysteine
- bucillamine
- bucillamine
- bucillamine
- bucillamine
- bucillamine
- bucillamine
- bucillamine
- bucillamine
- l-cysteine, n-(2-mercapto-2-methyl-1-oxopropyl)-
- n-(2-mercapto-2-methylpropionyl)-l-cysteine
- rimatil
- sa 96
- sa-96
- thiobutarit
- tiobutarit
- tiobutarit
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04504734 | Phase 3 | Nov 27, 2020 | Revive Therapeutics, Ltd. |
| NCT03660059 | Phase 3 | Sep 30, 2018 | Astellas |
| NCT02942420 | Phase 2 | May 1, 2017 | Revive Therapeutics, Ltd. |
| NCT02330796 | Phase 2 | Apr 1, 2015 | Revive Therapeutics, Ltd. |
| NCT02373202 | Phase 3 | Feb 1, 2015 | Regeneron, Sanofi |
| NCT00716248 | Phase 4 | Jan 1, 2007 | Keio University, Saitama Medical University |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Revive Therapeutics, Ltd. | For profit | 3 | 3 | 2 | 2015 |
| Astellas | For profit | 1 | 1 | 1 | 2018 |
| Keio University | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Regeneron | For profit | 1 | 0 | 1 | 2015 |
| Saitama Medical University | Academic/Hospital | 1 | 1 | 1 | 2007 |
| Sanofi | For profit | 1 | 1 | 1 | 2015 |
6 organizations
Page 1 / 1